Clinical Trials Logo

Recurrent Malignant Mesothelioma clinical trials

View clinical trials related to Recurrent Malignant Mesothelioma.

Filter by:

NCT ID: NCT01861301 Terminated - Clinical trials for Recurrent Malignant Mesothelioma

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01503177 Recruiting - Clinical trials for Recurrent Malignant Mesothelioma

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM). The investigators anticipate that the intrapleural of the vaccine strain measles virus will enable the virus to specifically infect and kill cancer cells and spare, without damaging normal cells. Furthermore, the investigators expect the measles virus to trigger an anti-tumor immune response which will result in additional destruction of the tumor by immune cells

NCT ID: NCT01325753 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Start date: March 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.

NCT ID: NCT01126346 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

HOPE
Start date: May 2010
Phase: N/A
Study type: Interventional

RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies. PURPOSE: This clinical trial studies quality of life and survivorship care in patients undergoing surgery and chemotherapy for peritoneal surface malignancies.

NCT ID: NCT01105390 Withdrawn - Clinical trials for Recurrent Malignant Mesothelioma

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving AMG 102 together with pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma. Monoclonal antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability of tumor cells to grow or spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AMG 102 together with pemetrexed disodium and cisplatin may kill more tumor cells

NCT ID: NCT01064648 Active, not recruiting - Clinical trials for Recurrent Malignant Mesothelioma

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Start date: March 15, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.

NCT ID: NCT00459862 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00392444 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Start date: February 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

NCT ID: NCT00365053 Completed - Clinical trials for Recurrent Malignant Mesothelioma

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery. PXD101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00309946 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor